| DIRECT COMPETITOR COMPARISON | |
| COR | CEPH | LLY | SHPGY | Industry | | Market Cap: | 10.26M | 4.12B | 42.40B | N/A | 161.24M | | Employees: | 27 | 2,780 | 40,500 | N/A | 95 | | Qtrly Rev Growth (yoy): | N/A | 10.20% | 6.80% | N/A | 20.50% | | Revenue (ttm): | N/A | 2.16B | 21.11B | N/A | 46.74M | | Gross Margin (ttm): | N/A | 82.61% | 82.33% | N/A | 68.58% | | EBITDA (ttm): | -9.83M | 703.00M | 7.74B | N/A | -7.12M | | Oper Margins (ttm): | N/A | 24.96% | 30.97% | N/A | 2.25% | | Net Income (ttm): | -12.32M | 280.69M | -216.00M | N/A | N/A | | EPS (ttm): | -0.244 | 3.618 | -0.197 | N/A | -0.17 | | P/E (ttm): | N/A | 15.27 | N/A | N/A | 17.12 | | PEG (5 yr expected): | N/A | 0.85 | 4 | 2.2 | 1.04 | | P/S (ttm): | N/A | 1.93 | 2.04 | N/A | 4.17 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.50 | -1.02% | 57.19B | 12.32 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 46.92 | -1.12% | 13.57B | 15.70 | | Genzyme Corp. | GENZ | 51.07 | -0.87% | 13.55B | 29.12 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.56 | -0.89% | 41.90B | 18.00 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.95 | -1.85% | 8.91B | 1019.39 | | Teva Pharmaceutical Industries Limited | TEVA | 52.88 | -0.53% | 46.59B | 48.38 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 36.96 | -2.25% | 3.92B | 19.05 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.95 | -1.08% | 2.97B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.01 | -1.53% | 5.50B | 110.49 | | Pfizer Inc. | PFE | 18.25 | -1.83% | 147.27B | 15.16 | | Johnson & Johnson | JNJ | 62.89 | -0.65% | 173.52B | 13.73 | | GlaxoSmithKline plc | GSK | 42.26 | -1.45% | 107.13B | 13.21 | | Sanofi-Aventis | SNY | 38.43 | -2.61% | 100.35B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.38 | -0.84% | 125.78B | 16.58 | | RHHBY.PK | 41.46 | -1.96% | N/A | N/A | | AstraZeneca plc | AZN | 45.29 | -2.35% | 65.67B | 9.09 | | Abbott Laboratories | ABT | 54.08 | -0.61% | 83.65B | 14.65 | | Bristol-Myers Squibb Co. | BMY | 25.38 | -1.05% | 50.28B | 13.13 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | LLY | | [$$] Jim Cramer's Best Blogs
Sat 8:54am -
at RealMoney by TheStreet.com | | • | LLY | | [$$] Glimmers in a Fading Year
Sat 8:03am -
at Barrons.com | | • | LLY | | TradingMarkets 7 Stocks You Need to Know for Monday
Fri 1:06pm -
TradingMarkets.com | | • | LLY | | Byetta Label Revised
Fri 12:52pm -
Zacks.com | | • | CEPH | | [$$] Sorting Through the Stock Laggards of 2009
Fri 11:29am -
at Barrons.com | | • | LLY | | This Big Winner Has Hit Its Prime
Fri 11:12am -
at Motley Fool | | • | SHPGY | | SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
Fri 8:39am -
EDGAR Online | | • | LLY | | 5 Good Dividend Plays
Fri 3:26am -
at Seeking Alpha | | • | LLY | | Sitting Atop An Earnings Powder Keg
Wed, Nov 25 -
at Forbes.com | | • | CEPH | | Cephalon Settles Barr Challenge
Wed, Nov 25 -
Zacks.com | | • | SHPGY | | Shire's Gaucher Candidate Seeks EU Nod
Wed, Nov 25 -
Zacks.com | | • | CEPH | | [$$] Stocks in the Spotlight Monday
Tue, Nov 24 -
at Barrons.com | | • | SHPGY | | Shire moves to advance Gaucher drug
Tue, Nov 24 -
at bizjournals.com | | • | SHPGY | | Biotech Stocks: Shire climbs, Pfizer falls in early trading
Tue, Nov 24 -
at MarketWatch | | • | CEPH | | H-P: Analysts' Upgrades, Downgrades
Tue, Nov 24 -
at TheStreet.com | | • | SHPGY | | Shire applies for Euro approval of Gaucher drug
Tue, Nov 24 -
at MarketWatch | | • | SHPGY | | Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease
Tue, Nov 24 -
PR Newswire | | • | CEPH | | Cephalon upgraded by Jefferies & Co
Tue, Nov 24 -
Briefing.com | | • | CEPH | | [$$] Verizon Advances 3%; Chevron, Exxon Rise
Tue, Nov 24 -
at The Wall Street Journal Online | | | All Headlines for these symbols... |
|
|
|
1.48% Nasdaq 
Competitors
